Investment Rating - The investment rating for the company is "Accumulate" (maintained) with a current price of 3.38 CNY and a target price of 3.64 CNY over a 6-month period [1]. Core Insights - The company is expected to achieve a net profit attributable to shareholders of 350 million to 420 million CNY in 2025, representing a year-on-year growth of 50.37% to 80.44% [5][8]. - The core driver of this growth is attributed to a non-recurring investment income of 132 million CNY from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd. [8]. - The company’s main business is showing steady recovery, with a projected net profit excluding non-recurring items of 185 million to 220 million CNY, reflecting a moderate growth of 0.92% to 20.02% [8]. Summary by Sections Market Data - Total share capital is 2,232.03 million shares, with a circulation ratio of 98.46% [2]. - The highest and lowest stock prices over the past 12 months were 4.08 CNY and 2.12 CNY, respectively [2]. Performance Metrics - The company has shown relative returns of -3.81% over 1 month, 2.98% over 3 months, and 17.42% over 12 months compared to the CSI 300 index [4]. - Absolute returns were -3.70% over 1 month, 8.68% over 3 months, and 35.74% over 12 months [4]. Financial Forecast - Revenue projections for 2025-2027 are 2,252.80 million CNY, 2,392.24 million CNY, and 2,637.93 million CNY, with growth rates of -7.70%, 6.19%, and 10.27% respectively [10]. - Net profit forecasts for the same period are 352.59 million CNY, 291.40 million CNY, and 351.19 million CNY, with growth rates of 51.48%, -17.35%, and 20.52% respectively [10]. Investment Thesis - The company is positioned to benefit from a dual-track development in the pharmaceutical industry, supported by local policy incentives, which may catalyze performance growth [8]. - The product matrix covers over 300 drug registration certificates across various therapeutic areas, enhancing market penetration [8]. - The company is expected to maintain stable profitability in the existing market while expanding its pipeline and innovating in traditional Chinese medicine [8].

Core Viewpoint - The company expects a significant increase in net profit for 2025, projecting a range of 350 million to 420 million yuan, representing a year-on-year growth of 50.37% to 80.44% [1] Financial Performance - The basic earnings per share are estimated to be between 0.1597 yuan and 0.1917 yuan [1] - The increase in performance is attributed to strong sales growth of core products, including injectable multivitamins, potassium chloride sustained-release tablets, and other key medications [1] Cost Management - The company has improved internal management, leading to a noticeable reduction in sales and administrative expenses compared to the same period last year [1] Non-Recurring Income - In December 2025, the company received 132 million yuan from the sale of equity in Guangzhou Yuheng Biotechnology Co., Ltd., which will be included in the investment income for 2025 as a non-recurring gain [1]

Core Viewpoint - The company, Yuheng Pharmaceutical (002437.SZ), expects a significant increase in net profit for 2025, projecting a range of 350 million to 420 million yuan, representing a growth of 50.37% to 80.44% year-on-year, while the net profit excluding non-recurring gains is expected to be between 185 million and 220 million yuan, reflecting a growth of 0.92% to 20.02% year-on-year [1] Group 1 - The sales of several core products, including injectable multivitamins, potassium chloride sustained-release tablets, and other medications, have shown substantial and steady growth [1] - The company has improved internal management, achieving notable results in cost reduction and efficiency enhancement, with both sales and management expenses decreasing compared to the previous year [1] - In December 2025, the company received the final payment and interest of 132 million yuan from the sale of its stake in Guangzhou Yuheng Biotechnology Co., Ltd., which will be included in the company's investment income for 2025 as a non-recurring gain [1]